Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Prepaid Assets (2017 - 2025)

Aclaris Therapeutics has reported Prepaid Assets over the past 9 years, most recently at $4.2 million for Q2 2025.

  • Quarterly results put Prepaid Assets at $4.2 million for Q2 2025, down 32.41% from a year ago — trailing twelve months through Jun 2025 was $4.2 million (down 32.41% YoY), and the annual figure for FY2024 was $12.0 million, up 27.37%.
  • Prepaid Assets for Q2 2025 was $4.2 million at Aclaris Therapeutics, up from $3.2 million in the prior quarter.
  • Over the last five years, Prepaid Assets for ACRS hit a ceiling of $19.7 million in Q3 2023 and a floor of $3.2 million in Q1 2025.
  • Median Prepaid Assets over the past 5 years was $9.0 million (2021), compared with a mean of $9.3 million.
  • Biggest five-year swings in Prepaid Assets: skyrocketed 401.74% in 2021 and later tumbled 78.32% in 2024.
  • Aclaris Therapeutics' Prepaid Assets stood at $13.0 million in 2021, then rose by 3.85% to $13.5 million in 2022, then decreased by 29.96% to $9.5 million in 2023, then increased by 27.37% to $12.0 million in 2024, then plummeted by 65.1% to $4.2 million in 2025.
  • The last three reported values for Prepaid Assets were $4.2 million (Q2 2025), $3.2 million (Q1 2025), and $12.0 million (Q4 2024) per Business Quant data.